Novo Nordisk(US:NVO) Benzinga·2025-12-24 05:10Economic Growth - U.S. gross domestic product (GDP) expanded at a 4.3% annualized pace in the third quarter, surpassing estimates of 3.3% and marking the fastest growth rate in two years [2] - This economic strength led traders to reduce expectations for near-term Federal Reserve easing, with the probability of a 25-basis-point cut in late January now at approximately 15%, down from 20% the previous day [2] Industrial Production and Orders - U.S. industrial production increased by 0.1% month-over-month in October and November [3] - Durable goods orders fell by 2.2% month-over-month to $307.4 billion in October, contrasting with a revised growth of 0.7% in September and against market estimates of a 1.5% decline [3] Stock Market Performance - U.S. stocks closed higher, with the S&P 500 reaching a record level, driven by a surge in artificial intelligence stocks [1] - The Dow Jones increased by around 80 points to 48,442.41, while the S&P 500 rose by 0.46% to 6,909.79, and the Nasdaq Composite jumped by 0.57% to 23,561.84 during the session [4] - Most sectors on the S&P 500 ended positively, particularly communication services, information technology, and energy stocks, while consumer staples and health care stocks declined [4] Company-Specific News - Novo Nordisk A/S shares rose over 7% following FDA approval of its Wegovy pill [3]